Zhang Yanmei, Tortorella Micky D, Wang Yican, Liu Jianqi, Tu Zhengchao, Liu Xiaorong, Bai Yang, Wen Dingsheng, Lu Xin, Lu Yongzhi, Talley John J
Drug Discovery Pipeline, Guangzhou Institutes of Biomedicine and Health , Science City, Guangzhou 510530, P. R. China.
Department of Chemistry, St. Louis University , St. Louis, Missouri 63108, United States ; Euclises Pharmaceuticals, St. Louis, Missouri 63108, United States.
ACS Med Chem Lett. 2014 Jul 27;5(10):1162-6. doi: 10.1021/ml500299q. eCollection 2014 Oct 9.
We designed a series of specifically deuterated benzopyran analogues as new COX-2 inhibitors with the aim of improving their pharmacokinetic properties. As expected, the deuterated compounds retained potency and selectivity for COX-2. The new molecules possess improved pharmacokinetic profiles in rats compared to their nondeuterated congeners. Most importantly, the new compounds showed pharmacodynamic efficacy in several murine models of inflammation and pain. The benzopyran derivatives were separated into their enantiomers, and the activity was found to reside with the S-isomers. To streamline the synthesis of the desired S-isomers, an organocatalytic asymmetric domino oxa-Michael/aldol condensation reaction was developed for their preparation.
我们设计了一系列经过特定氘代的苯并吡喃类似物作为新型COX-2抑制剂,旨在改善其药代动力学性质。正如预期的那样,氘代化合物保留了对COX-2的效力和选择性。与未氘代的同类物相比,新分子在大鼠中具有改善的药代动力学特征。最重要的是,新化合物在几种炎症和疼痛的小鼠模型中显示出药效学功效。苯并吡喃衍生物被拆分为对映体,发现活性存在于S-异构体中。为了简化所需S-异构体的合成,开发了一种有机催化的不对称多米诺氧杂-迈克尔/羟醛缩合反应来制备它们。